RE: Accelerated approval FDA chat GPT27 Jun 2024 00:56
Https://academicentrepreneurship.pubpub.org/pub/einr3b30
It contains the following passages
. Orphan drug trials are generally single arm (no placebo arm), nonrandomized, and open label. Safety Phase 1 trials are not usually required, and Phases 2 and 3 can be combined when the patient population is very low.
. Sponsors of an orphan drug can make use of expedited Food and Drug Administration (FDA) programs such as the Fast Track, Breakthrough Therapy, and Priority Review designations, as well as the Accelerated Approval pathway and unique grant funding opportunities, such as the Orphan Products Clinical Trials Grant program.
Thanks to a prior CTSFO post.
+++
A Turner Pope marketing document 28.05.2024:
"Given AVA6000βs Orphan Drug status, it is possible to gain an accelerated FDA approval based on just two clinical
trial phases, with a view to significantly reducing the time and investment required to get it to market. Although a
Phase 3 study must be near-completion at the time of the submission, registrational studies can be based
substantially on clinical results from the Phase 2 trials."
The AGM Business Update transcript contains:
"In an ideal world, we may be able to use that phase two trial for an approval strategy called an
accelerated approval that will be in the United States.
One key aspect of the accelerated approval strategy in the US is that the phase three trial must be
ongoing at the time of that submission." - CC.
She seems to be concentrating on accelerated FDA approval only, when other (see above) options are available.
Sign In
Follow the stocks
